DEPRESSION 2: Major Depressive Disorder Remission as a Goal: A Measurement-Based Approach

In a majority of primary care clinics, physicians have time constraints that limit the patient's visits thus often focusing on the chief complaint. By providing a screening tool that is incorporated into the vital assessment process, screening for depression can easily be adapted into the workflow. Screening for depression has a CPT code that is reimbursable by CMS and commercial insurance.

This training will provide the content and competence for primary care providers to feel confident in their ability to screen for and identify patients with depression.

Additionally, this training will provide instructions on how to treat depression using a measurement based approach based on how the patient responds to questions on various assessments addressing symptom severity, medication compliance, and overall well-being.

Method of Participation

This activity is in a video and synchronized slides format with a closed captions option. A text and slides (PDF) viewing option is also available. References are linked to online resources.

To receive a maximum of 0.75 AMA PRA Category 1 Credit(s)™ you should:

  • View the presentations in this enduring material.
  • Complete the posttest (you must answer 4 out of 5 questions correctly).
  • Complete and submit the CME registration and evaluation forms.

The estimated time to complete this activity, including review of the materials, is 0.75 hours.

Hardware/software requirements: Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox, and Google Chrome.

If you have questions about the participation process, please e-mail the UT Southwestern Medical Center, cmeregistrations@utsouthwestern.edu or phone 214-648-3138.

Accreditation/Credit Designation

The UT Southwestern Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The UT Southwestern Medical Center designates this enduring material activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Term of Approval

September 2014 through September 2016. Original release date: September 2014.

Peer Review

In July 2014, this continuing medical education online enduring material was reviewed by E. Will Clark, M.D., Instructor, University of Texas Southwestern Medical Center, Dallas, Texas. To ensure the continued scientific relevance of this enduring material, its content will be reviewed again in September 2016.

Disclosures: Nothing to disclose.

Program Director

Robert Rege, MD
Professor of Surgery
Chairman, Office of Continuing Medical Education
University of Texas Southwestern Medical Center
Dallas, Texas

Disclosure: Nothing to disclose

Disclaimer

This CME activity is designed for use by healthcare professionals for educational purposes only. Information and opinion offered by the contributors represent their viewpoints. Conclusions drawn by the participant should be derived from careful consideration of all available scientific information. Prescription information and use of medical devices should be undertaken only after confirmation of information by consulting the FDA-approved uses and information.

This CME activity has been planned to be well-balanced and objective in discussion of comparative treatment regimens, and the the activity format allows for the free scientific exchange of ideas. Information and opinions offered by the speakers represent their viewpoints. Conclusions drawn by the audience should be derived from careful consideration of all available scientific information.

Links are provided to other Internet sites solely for the convenience of users. Once you link to another site, you are subject to the site"s terms and conditions of use including copyright and licensing restrictions.

Disclosure

The UT Southwestern Medical Center makes every effort to develop CME activities that are scientifically based, accurate, current, and objectively presented. In accordance with the Accreditation Council for Continuing Medical EducationStandards for Commercial Support™ the UT Southwestern Medical Center has implemented a mechanism requiring everyone in a position to control the content of an educational activity (e.g., directors, planning committee members, contributors, peer reviewers) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships: 1) at the time of the activity or within 12 months prior; and 2) of their spouses/partners.

The UT Southwestern Medical Center does not view the existence of interests or relationships with commercial entities as implying bias or decreasing the value of a presentation. It is up to the participants to determine whether the interests or relationships influence the presenter with regard to exposition or conclusions.

If at any time during this activity you feel that there has been commercial or promotional bias, please inform us by using the commercial bias comments box in the evaluation form. Please answer the questions about balance in the CME activity evaluation candidly.

The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:

Madhukar H. Trivedi, MD, Presenter
Betty Jo Hay Distinguished Chair in Mental Health
Professor of Psychiatry
Director Comprehensive Center for Depression
Department of Psychiatry
University of Texas Southwestern Medical Center
Dallas, Texas
Disclosure:
Consulting: Madhukar H. Trivedi is or has been an advisor/consultant to, Alkermes, AstraZeneca, Bristol-Myers Squibb Company, Cephalon, Inc., Cerecor, Concert Pharmaceuticals, Inc., Eli Lilly & Company, Evotec, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Global Services, LLC/Janssen Pharmaceutica Products, LP/Johnson & Johnson PRD, Lundbeck, MedAvante, Medtronic, Merck, Mitsubishi Tanabe Pharma Development America, Inc., Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Pfizer Inc., Phoenix Marketing Solutions, Rexahn Pharmaceuticals, Ridge Diagnostics, Roche Products Ltd ., Sepracor, SHIRE Development, Sunovion, Takeda, Vivus, and Wyeth-Ayerst Laboratories.

Research Activities: In addition, he has received research support from: Agency for Healthcare Research and Quality (AHRQ), National Alliance for Research in Schizophrenia and Depression, National Institute of Mental Health, National Institute on Drug Abuse, National Institute of Diabetes and Digestive Disorders.

Formal Advisory: Member, Scientific Advisory Board for the Canadian Biomarker Integration Network for Depression (CAN BIND) project (2014). Special Emphasis Panel, ZMH1 ERB – I (04), National Institute of Mental Health (NIMH), Mentored Career Development Award to Build Research Capacity in Global Mental Health, April 9, 2014.

The following individual(s) has/have reported no financial or other relationships with commercial entities whose products/services may relate to the educational content of this activity:

E. Will Clark, MD, Peer Reviewer
Instructor
Department of Psychiatry
University of Texas Southwestern Medical Center
Dallas, Texas
Disclosure: Nothing to disclose

Ericka Harden-Dews, JD, CCMEP, CME Staff
Associate Director
Office of Continuing Medical & Public Education
University of Texas Southwestern Medical Center
Dallas, Texas
Disclosure: Nothing to disclose

Anne N. Perch, MBA, CCMEP, CME Staff
Assistant Vice President
Office of Continuing Medical & Public Education
University of Texas Southwestern Medical Center
Dallas, Texas
Disclosure: Nothing to disclose

Deborah Phillips, BSN, RN, MPH, CME Staff
CE Program Coordinator
Office of Continuing Medical & Public Education
University of Texas Southwestern Medical Center
Dallas, Texas
Disclosure: Nothing to disclose

Some drugs/devices identified during this activity may have United States Food and Drug Administration (FDA) clearance for specific purposes only or for use in restricted research settings. The FDA has stated that it is the responsibility of the individual physician to determine the FDA status of each drug or device that he/she wishes to use in clinical practice and to use the products in compliance with the applicable law.

The UT Southwestern Medical Center requires that all contributors disclose an unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products, and provide adequate scientific and clinical justification for such use. Physicians are urged to fully review all the available data on products or procedures before using them to treat patients.

Target Audience

This CME activity is designed to meet the educational needs of primary care physicians, nurse practitioners, and physician assistants, particularly those serving underserved and vulnerable populations.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Employ the use of standardized measures of treating major depressive disorder (MDD).
  • Integrate the use of a measurement-based care approach to treat MDD.
  • Recognize when to adjust treatments and assess how to treat for full remission of symptoms of MDD.
Course summary
Available credit: 
  • 0.75 AMA
  • 0.75 Attendance
Course opens: 
09/01/2014
Course expires: 
09/30/2018
Cost:
$0.00

Madhukar H. Trivedi, MD, Presenter
Betty Jo Hay Distinguished Chair in Mental Health
Professor of Psychiatry
Director Comprehensive Center for Depression
Department of Psychiatry
University of Texas Southwestern Medical Center
Dallas, Texas

Disclosures:

Consulting: Madhukar H. Trivedi is or has been an advisor/consultant to, Alkermes, AstraZeneca, Bristol-Myers Squibb Company, Cephalon, Inc., Cerecor, Concert Pharmaceuticals, Inc., Eli Lilly & Company, Evotec, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Global Services, LLC/Janssen Pharmaceutica Products, LP/Johnson & Johnson PRD, Lundbeck, MedAvante, Medtronic, Merck, Mitsubishi Tanabe Pharma Development America, Inc., Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Pfizer Inc., Phoenix Marketing Solutions, Rexahn Pharmaceuticals, Ridge Diagnostics, Roche Products Ltd ., Sepracor, SHIRE Development, Sunovion, Takeda, Vivus, and Wyeth-Ayerst Laboratories.

Research Activities: In addition, he has received research support from: Agency for Healthcare Research and Quality (AHRQ), National Alliance for Research in Schizophrenia and Depression, National Institute of Mental Health, National Institute on Drug Abuse, National Institute of Diabetes and Digestive Disorders.

Formal Advisory: Member, Scientific Advisory Board for the Canadian Biomarker Integration Network for Depression (CAN BIND) project (2014). Special Emphasis Panel, ZMH1 ERB – I (04), National Institute of Mental Health (NIMH), Mentored Career Development Award to Build Research Capacity in Global Mental Health, April 9, 2014.

Available Credit

  • 0.75 AMA
  • 0.75 Attendance

Accreditation Period

Course opens: 
09/01/2014
Course expires: 
09/30/2018

Price

Cost:
$0.00
Please login or create an account to take this course.

Required Hardware/software

Hardware/software requirements: Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox, and Google Chrome.